

Index

- γ -aminobutyric acid (GABA), 75–6
 receptors, 212
 roles, 114
 mice, 141
 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propanoic acid (AMPA), 221
 receptors, 177, 213
 5-HT *see* serotonin
 5-methylcytosine (5-mC), 127–8
 formation, 128–9
 A_{2A} receptor knockout mice, sleep, 76–7
 AA-NAT gene, and delayed sleep phase disorder, 328–9
 ABCC9 gene, 24
 roles, 43
 variants, 43
 ABCD1 gene, 375
 abnormal sleep, and sleep disorders, 35–9
 Acad10 gene, roles, 112–14
 Acads gene, 96–7
 roles, 109
 acetyl-L-carnitine (ALCAR), 96–7
 acetylcholine (ACh), roles, 176, 211
 actuators, in optogenetics, 68
 acute stress disorder, prevalence, 355–6
 acyl CoA dehydrogenase, 96–7
 ADA gene, 375
 adeno-associated virus (AAV), cre-dependent, 68, 70
 adenosine_{2A} receptors ($A_{2A}R$ s)
 genes, 107
 roles, 78
 adenosine
 accumulation, 86–7
 biosynthesis, 86, 88
 release, 214
 roles
 mice, 141–2
 in sleep deprivation, 177
 in sleep regulation, 77–8, 95, 107
 sleep induction, 77
 adenosine deaminase, 171–2, 375
 localization, 77–8
 studies, 80
 adenosine deaminase that act on RNA (ADAR) enzymes, 130–1
 adenosine monophosphate (AMP)
 formation, 85
 see also cyclic adenosine monophosphate (cAMP)
 adenosine monophosphate kinase (AMPK), 94–6
 adenosine triphosphate (ATP)
 exocytosis, 84
 gliotransmission, 88
 hydrolysis, 86
 and sleep regulation, 94–6
 S-adenosyl methionine (SAM), 128–9
 adolescents, psychiatric disorders, and delayed sleep phase disorder, 327–8
 ADORA1 gene, 141–2
 ADORA2 gene, 141–2
 ADORA3 gene, 141–2
 adrenoleukodystrophy, gene therapy, 375
 advanced intercrossed lines (AILs), 18
 advanced sleep phase disorder (ASPD), 165
 candidate gene studies, 328
 see also delayed sleep phase disorder (DSPD); familial advanced sleep phase disorder (FASPD)
 affected sib pair method, 3–4
 African American populations
 obstructive sleep apnea, 284–6
 pediatric obstructive sleep apnea, 304
 African sleeping sickness, 73–5
 age differences
 delayed sleep phase disorder, 330
 diurnal preferences, 199
 restless legs syndrome, 335
 aging, 214–15
 agouti-related protein (AgRP), 56
 ALA interneuron, 58
 ALD protein, deficiency, 375
 alleles
 causal, 7, 166
 frequencies, 166
 allostatic changes, to sleep homeostasis, 191–2
 almorexant, 249
 alpha-synuclein overexpressing (ASO) mice, 358
 Alzheimer's disease (AD)
 association analysis, 6–7
 circadian clock genes and, 357–8
 gene therapy, 375
 and long-term memory, 215
 sundowning, 357
 symptoms, 215, 357
 amygdala, functions, 246
 Amylase gene
 expression, 97
 transcripts, 98
 and waking, 96
 analysis of variance (ANOVA), 14
 Angelman syndrome (AS), symptoms, 133–4
 animal models
 anxiety disorders, 355, 356
 availability issues, 13
 bipolar disorder, 354–5
 for cognitive deficits induced by sleep deprivation, 171–84
 future research, 184
 familial advanced sleep phase, 320–4
 major depressive disorder, 353–4
 myotonic dystrophy, 267
 narcolepsy, 25, 243, 260, 377
 sequencing, 43
 sleep deprivation, 211
 limitations, 172
 in sleep genetics, 13–19
 sleep hypotheses, 91–2
 sleep mechanisms, 43
 sleep research, 54–5, 105–6, 172
 and memory, 208–9
 synaptic homeostasis hypothesis, 221
 see also bird models; inbred strains; outbred strains; rodent models
 anti-streptolysin O (ASO), 238
 antiepileptic drugs, 335
 anxiety disorders, 355–6
 apnea–hypopnea index (AHI), 27, 279, 284–6, 304
 apolipoprotein E (ApoE), 304–5
 polymorphisms, 215

Index

- AQP4* gene, 261–2
Arc gene, expression, 148, 219–20
 archaerhodopsin (Arch), 68
 arginine vasopressin (AVP), 357
ARNTL gene, 351–3
 arousal
 caffeine-induced, 79
 centers, 66
 control, 68–70
 disorders, genetic epidemiology, 37–8
 and locus coeruleus, 67–8
 mechanisms, 44
 and norepinephrine, 67–8
 see also paroxysmal arousals (PAs)
 neurons, optogenetic control of, 66–71
 systems, activation, 66–7
 association analysis
 complex phenotypes, 6
 future research, 10
 in genome-wide association studies, 8
 issues, 2
 association studies
 circadian entrainment, 165–6
 genetics, 13
 obstructive sleep apnea, 282–4
 see also candidate gene studies;
 genome-wide association studies (GWASs)
 associative learning paradigm, 45
 astrocytes
 adenosine release, 214
 early studies, 84
 electroencephalographic activity, 85
 gliotransmitter release, 213–14
 ion buffering, 85
 roles, 84
 in sleep regulation, 84–8
 somnogenic substances, secretion, 85–7
 astroglial regulation, of sleep, 84–8
Astyanax mexicanus (cavefish), sleep, 61–2
 ATP see adenosine triphosphate
 attention deficit hyperactivity disorder (ADHD), 9
 auditory discrimination, bird models, 180
 autoimmune diseases, association analysis, 6–7
 autoimmune hypothesis, and human leukocyte antigen, 237–8
 autosomal dominant cerebellar ataxia, deafness and narcolepsy (ADCA-DN)
 etiology, 133–4, 260
 genetics, 268
 and symptomatic narcolepsy, 263
 autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
 differential diagnosis, 367
 family studies, 368
 future research, 371
 genetic linkage studies, 367–8
 genetics, 365–71
 overview, 367–70
 point mutations, 370
 pathophysiology, 370–1
 aversive phototoxic suppression (APS)
 assay, 45
 Drosophila models, 181–2
 learning impairments, molecular pathways, 181–3
 avian models see bird models
 avoidance tasks, in sleep deprivation studies, 174
 BAC (bacterial artificial chromosome)
 plasmids, 321
BC034767 gene, 341
BDNF gene, expression, 143, 148, 219–20
 Beck Depression Inventory, 316–17
 bed nucleus of the stria terminalis (BNST), 244
 behavioral approaches, to sleep studies, 54
 Benington–Heller hypothesis, 85, 94
 limitations, 85
 bethanechol, 68
 biological clocks, synchronization, 122
 biological night, concept of, 191
 bipolar disorder (BPD), 354–5
 bird models, 178–80
 birds
 migration, 98
 cognitive function maintenance, 180
 sleep research, 172
blind-drunk (*Bdr*) mouse model, 357
BMAL1 gene, 99–100, 121, 133, 351–3
 and Alzheimer's disease, 357–8
 binding, 152–3
 deletion, 153–4
 deregulation, 360
 expression, 151–2, 353, 359
 mutations, 119
 roles, 107, 119–21
 and seasonal affective disorder, 354
 transcription, 150
BMAL1/Mop3 gene, 26
BMAL2 gene, polymorphisms, 356
 BMI see body mass index
bmm gene, 97
 mutations, 98
 body mass index (BMI)
 and obstructive sleep apnea, 284–6, 292
 and sleep duration, 92
 borderline personality disorder (BLPD), 359–60
 brain
 changes, aging and, 214
 sites, and symptomatic narcolepsy, 261
 and sleep functions, 219
 brain metabolism, and insomnias, 231
 brain regions, and memory, 209
 brain size, and sleep duration, 91–2
 brain-derived neurotrophic factor (BDNF), 84, 143
 secretion, 85
 brainstem, switching, 104–5
brummer gene, mutations, 183
BTB9 gene, 43
BTBD9 gene, 9, 24, 339, 341, 343
 and restless legs syndrome, 342–3
 expression, 342–3
 variants, 339
 BXD RI mice, 108–9, 142
 C-reactive protein (CRP), 290, 304–5
Caenorhabditis elegans (nematode)
 advantages, 54–5
 characteristics, 54
 circadian rhythms, 57
 and *Danio rerio* compared, 54
 gene overexpression, 60
 genetic discovery methods, 59–60
 in sleep research, 54–62, 105–6
 future trends, 59–62
 lethargus, 57
 RNA interference, 342
 sleep, 57–9
 physiological activity, 60–1
 sleep-like behavior, 57–8
 caffeine
 arousal induction, 79
 sleep disturbance induction, 107
 and wakefulness, 78
 calcium, intracellular, 84
 calcium/calmodulin-dependent protein kinase II (CaMKII), 179–80
 cAMP see cyclic adenosine monophosphate
 candidate causal sleep genes (CCSGs), 112–15
 encoding, 114
 studies, 114
 transcriptional regulatory networks, 113
 candidate gene studies, 6–7, 9
 advanced sleep phase disorder, 328

- circadian rhythms, 23
 delayed sleep phase disorder, 328
Drosophila models, 43–4
 limitations, 22, 351
 obstructive sleep apnea, 27, 279–96
 future research, 296
 no associations, 285
 results, 286–96
 refinements, 284
 restless legs syndrome, 339
 sleep genetics, mice, 140–2
 systems genetics, 114
see also association studies
- carbamazepine, 366
 carnitine, deficiency, 255
 carnitine palmitoyl-transferase 1B, 243–4
 case-control studies, limitations, 282
 cataplexy, 248, 260
 and inherited diseases, 266
 and Niemann–Pick type C disease, 265
see also narcolepsy–cataplexy
- Catsup* gene, roles, 115–16
 Caucasian populations
 narcolepsy, genome-wide association studies, 255–7
 obstructive sleep apnea, 284–6
 pediatric obstructive sleep apnea, 304
 cavefish, sleep, 61–2
 central nervous system (CNS), 75
 cephalometry, 302–3
 cerebral demyelination, 375
 cerebrospinal fluid (CSF), orexin levels, 243
 cGMP-dependent kinase *see* protein kinase G (PKG)
- CGS21680, 75–6
 channelrhodopsin-2 (Chr2), 68, 173
 expression, 68–9
CHKB gene, 255, 258
 cholesterol, 219–20
 choline kinase beta, 243–4
 cholinergic neurons, 66, 211–12
CHRNA2 gene, 368–70
CHRNA4 gene, 367–8, 370
CHRN2 gene, 368, 370
 chromatin, 119–22
 higher-order remodeling, 127, 129
 immunoprecipitation, 152–3
 modifications, 129
 modifying enzymes, 129
 expression, 129
 remodeling, 131–2
 roles, 129
 structure, 129
- chromosomes
 bacterial artificial, plasmids, 321
 inbred strains, 16–17
 recombination, 2
 X chromosome inactivation, 127–8
- chronic insomnia
 age of onset, 229–30
 etiology, 227
 familial aggregation, 229–30
 familial components, 228–30
 genetic factors, 227–32
 heritability, 227–32
 measurements, 228
 prevalence, 227
 twin studies, 227, 229
- chronotherapies, 353
 chronotypes, vs. time-of-day preferences, 164
 circadian clock dysfunctions, etiology, 327
 circadian clock genes, 22
 and Alzheimer’s disease, 357–8
 and anxiety disorders, 355–6
 and bipolar disorder, 354–5
 and dementia associated with neurodegenerative diseases, 357–9
 and depressive disorders, 353–4
 expression, 351–3
 human, 352
 and Huntington’s disease, 358–9
 and major depressive disorder, 353–4
 and mental retardation, 360
 and mood disorders, 26, 353–5
 mutations, 43–4
 and Parkinson’s disease, 358
 and personality disorders, 359–60
 polymorphisms, 353
 and psychiatric disorders, 351–60
 future research, 360
 mechanisms, 359–60
- rodents, 351
 roles, 107
 and schizophrenia, 356–7
 and seasonal affective disorder, 354
 and sleep, humans, 351–3
 and Smith–Magenis syndrome, 360
 variants, 357
- circadian clocks
 aging and, 214–15
 and diurnal preferences, 197
 early, 162
 humans, 163
 input mechanisms, 122–3
 localization, 105, 150–1, 198–9
 mechanisms, 162
 model organisms, 162–3
 molecular components, 150–1
 use of term, 131
see also circadian pacemakers
- circadian entrainment, 313
 association studies, 165–6
 and daylight saving time, 168
 and familial syndromes, 165
 genetics, 162–8
 complexity, 166–8
 future research, 168
 humans, 163–8
 and light, 167–8
 and photoperiods, 168
 twin studies, 164–5
see also zeitgebers
- circadian genes, 327–32
 DNA methylation, 134–5
 humans, 162
- circadian pacemakers
 future research, 123
 genetic control, 119–23
see also circadian clocks
- circadian period
 and circadian phase, 318
 and diurnal preferences, correlations, 198–9
 long, 331
- circadian phase
 abnormal, 327
 and circadian period, 318
 and diurnal preferences, correlations, 198–9
 markers, 317–18
- circadian phenotype genetics, humans, 164–6
- circadian regulation
 and homeostatic regulation, 147–55
 crosstalk, 151
 future research, 154–5
 research background, 147–8
 individual differences, 327
 mechanisms, 147–8, 162
- circadian rhythm sleep disorders (CRSDs), 327
 differential diagnosis, 327–8
 etiology, 313
 future research, 324–5
 genetics, 313
 pathophysiology, 315
 symptoms, 313
see also delayed sleep phase disorder (DSPD); jet lag disorder; sleep–wake disorders
- circadian rhythms
 Caenorhabditis elegans, 57
 candidate gene studies, 23
 cellular, 313
 and diurnal preferences, 198
 and DNA methylation, 131
 Drosophila studies, 119
 epigenetics, 127–36
 future research, 135–6
 future research, 123
 genes, 99–100

Index

- circadian rhythms (cont.)
 genetics, 33–136
 and genomic imprinting, 133
 mechanisms, 189–90
 Mendelian alterations, 22–3
 molecular bases, 22
 and non-coding RNAs, 132–3
 non-transcriptional, 123
 physiological measurements, 317
 regulation, 105
 and RNA editing, 133
 roles, 313
 and sleep–wake cycles, 351
 studies, 351
 synchronization, 122–3, 351
 variability, 22–3
- circadian timing systems *see* circadian clocks
- CK1δ* gene, 22, 121, 351
 mutations, 4, 165
- CK1ε* gene, 22, 121, 351
 and delayed sleep phase disorder, 328–9
- Cleveland Family Study, 27, 279, 284–6, 304
- clinical depression *see* major depressive disorder (MDD)
- clinical interviews, insomnias, 228
- CLOCK* gene, 23–4, 99–100, 351
 and anxiety disorders, 356
 and bipolar disorder, 354–5
 and borderline personality disorder, 359–60
 and delayed sleep phase disorder, 328–9
 deletion, 122
 discovery, 119
 expression, 151–2, 353
 genome-wide transcription, 122
 homolog, 153–4
 hypomethylation, 199
 in mammals, 119–21
 mutations, 100, 119, 375
 polymorphisms, 26, 201–2, 232
 roles, 107, 119–21
 and schizophrenia, 356–7
- clock genes
 canonical, 99–100
 discovery, 119
 expression, 122
 and elevated sleep pressure, 151–3
 high-density markers, 24
 humans, 162–3
 identification, 119
 and insomnias, 26
 mutations, 22, 43–4, 201–2
 and sleep homeostasis, 153–4
 paralogs, 121–2
- polymorphisms, 201–2, 353
 roles, 107, 151
 in sleep pressure, 151, 153
 and synaptic element regulators, 154
see also circadian clock genes
- Clock* mutant mice, 100, 354–5
- CLOCK*–*BMAL1* complex, 150
- clocks
 biological, synchronization, 122
 peripheral, 123
 single-cell research, 163
see also circadian clocks
- CNS *see* central nervous system
- Coffin–Lowry syndrome (CLS), 266
- cognition, and sleep deprivation, rodents, 174–5
- cognitive deficits
 and aging, 214
Drosophila models, 183–4
 and sleep deprivation, 171, 193
 animal models, 171–84
 bird models, 178–80
Drosophila models, 180–4
 future research, 184
 individual differences, 193
 mechanisms, 177–8
 rodent models, 172–8
 and sleep duration, 191
- cognitive function
 maintenance, during bird migration, 180
 and pediatric obstructive sleep apnea, 306–7
- cognitive impairments *see* cognitive deficits
- cognitive tests
 and sleep deprivation, 171–2
 rodents, 174
- Collaborative Cross (CC), 111
 goals, 15
 and recombinant inbreds, 15–16
- common-variant common-disease hypothesis, 7
- complex phenotypes
 association analysis, 6
 classification, 5–6
 factors affecting, 5
 genome-wide association studies, 7
 linkage mapping, 5–6
 studies, methodology, 6–9
- complex trait analyses
 goals, 6
 in sleep genetics, 13–19
- complex traits
 categorical, 5–6
 continuous, 5–6
 future research, 22
 genetic mapping, 1–2
 studies, 6
- congenic lines, 17–18
- continuous positive airway pressure (CPAP), in obstructive sleep apnea treatment, 296
- copy number variations (CNVs), 7–8
- Cornelia de Lange syndrome, etiology, 133–4
- corticosteroids, 214
- cortisol, 214–15
- courtship conditioning, 45–6, 50
Drosophila models, 184
- CPT1B* gene, 9, 255, 258
 and narcolepsy, 255
- CREB1* gene, 341–2
- Creutzfeldt–Jakob disease (CJD), genetic mutations, 231
- CRH* gene, 370–1
- CRY* proteins, 121–2
- CRY1* gene, 22, 119–22, 150, 353
 deregulation, 360
 expression, 153–4
 and schizophrenia, 357
- CRY2* gene, 22, 119–22, 150
 hypermethylation, 199
 expression, 153–4
- cryptochromes, 22
- CSNK1D*
 gene, 320, 323–4
 circadian phenotypes, 324
 expression, 320–1
 mutations, 319–20
 transgenic mice, 324
- CSNK1E* gene, 319–20
- Cullin-3, 49–50
- cyanobacteria
 circadian clocks, 162
 circadian rhythms, 123
- cyc⁰¹* gene, 43–4
- Cycle* gene, 153
- cyclic adenosine monophosphate (cAMP)
 levels, 58
 response element-binding protein (CREB), 152–3
 and memory, 213
 signaling, 44, 58, 212–13
- cyclic behavior, mammals, 122
- cyclic guanosine monophosphate (cGMP), encoding, 46
- cyclin A, 50
- cytokines, secretion, 87–8

- DA *see* dopamine
- Danio rerio* (zebrafish), 54–6
sleep, 54–7
physiological activity, 60–1
in sleep research, 54–62, 105–6
future trends, 59–62, 184
- daylight saving time, and circadian entrainment, 168
- daytime sleepiness, 35
see also excessive daytime sleepiness (EDS)
- db/db* mice, 93
- Dbp* gene
absence of, 153–4
expression, 151–2
- dBTD9* gene, 342–3
- dDA1 *see* *Drosophila* D1 receptor (dDA1)
- DEC2* gene, 23
mutations, 26, 43, 140
- declarative memory, 209–10
- delayed sleep phase disorder (DSPD), 165, 327–32
and adolescent psychiatric disorders, 327–8
age differences, 330
candidate gene studies, 328
diagnosis, 23, 327–8
and diurnal preferences, 329–30
etiology, 327–8
and evening preference, 327–8, 331
future research, 331
gene therapy, 375
genetics, 23, 328–9
heritability, 328
individual differences, 331
and light, 331
and melatonin, 328, 330–1
overview, 327–8
and *PER3* gene, 328–31
prevalence, 327–8
and sleep deprivation, 330
symptoms, 327–8
treatment, 331
see also advanced sleep phase disorder (ASPD)
- delta sleep inducing peptide (DSIP), 131–2
- delta waves, and sleep intensity, 105
- dementias
associated with neurodegenerative diseases, circadian clock genes and, 357–9
genetic mutations, 231
see also Alzheimer's disease (AD)
- depression, measures, 316–17
- depressive disorders
circadian clock genes and, 353–4
see also bipolar disorder (BPD); major depressive disorder (MDD)
- Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), 69–70
- diabetes type 2, and obstructive sleep apnea, 293
- diacylglycerol (DAG), formation, 84
- Diagnostic and Statistical Manual of Mental Disorders (DSM)*
insomnias, 228
sleep disorders, 227–8
- diazepam, sleep induction, 56
- Dilp2* gene, 48
- dim-light melatonin onset (DLMO), 313–15, 317–18
- discs-large protein, 50
- diseases, and human leukocyte antigen, 238–9
- diurnal preferences
age differences, 199
and circadian clocks, 197
and circadian period, correlations, 198–9
and circadian phase, correlations, 198–9
and circadian rhythms, 198
and delayed sleep phase disorder, 329–30
determinants, 197, 199
future research, 204
and genetic variations, 201–2
heritability, 201, 328
inheritance, 199–201
issues, 197
measurement, 197–8
overview, 203–4
and *PER3* gene, 200, 202–3
sex differences, 199
and sleep duration, 199
and sleep–wake timing, 199–201
see also human diurnal preferences
- diurnal type
twin studies, 34
see also morningness–eveningness
- diversity outbred (DO) mice, 111
- dizygotic (DZ) twins
chronic insomnia studies, 227, 229
diurnal type studies, 34
electroencephalograms, 139–40
heritability, 6, 105–6
insomnia studies, 36
restless legs syndrome studies, 336
sleep genetics, 140
sleep length studies, 34–5
sleep quality studies, 35
variability studies, 33
- DMPK* gene, 266–7
- DMT1* gene, 342
- DNA
mutations, 1
variations, 1–2
hydroxymethylation, 127–8
definition, 127–8
epigenetics, 127–9
localization, 129
methylation, 127–8
and circadian rhythms, 131
epigenetics, 127–9
localization, 129
and pediatric obstructive sleep apnea, 307–8
roles, 127–8
studies, 134–5
methyltransferases (DNMTs), 127–8
roles, 128–9
- DNMT1* gene, 257, 263, 268
expression, 263
mutations, 133–4
structure, 263
and symptomatic narcolepsy, 263
- Dnmt3b* gene, 131
- dominant-negative soluble *N*-ethylmaleimide-sensitive fusion protein attachment protein receptor (dnSNARE), 86–7
and sleep deprivation, 94–6
- donepezil, 215
- dopamine (DA), 56
active transporter (DAT) knockout mice, 141
beta hydroxylase, 56
expressing neurons, 48–9
in reinforcement learning, 44
receptors, subtypes, 141
signaling, 181–2
transporter gene, 44
- dopaminergic drugs, 335
- dorsal fan shaped body, 48
- dorsal raphe nuclei (DRN), 66
- Down's syndrome, 360
- Dox (doxycycline), 86
- DP₁ receptor
knockout mice, sleep, 76–7
roles, 78
- Dps1* gene, roles, 108–9, 142
- DQA1*0102, 37
- DQB1*0602, 25, 37
- DRD2* gene, polymorphisms, 356–7
- Drosophila* spp. (fruit flies), 320–1
candidate gene studies, 43–4
circadian entrainment studies, 164–5
circadian rhythm studies, 119
courtship conditioning, 184
dopamine signaling, 181–2

Index

- Drosophila* spp. (fruit flies) (cont.)
 early studies, 2
Elp3 gene, 132
 foraging alleles, 183
foraging gene, 98–9
 forward genetic screens, 49–50, 59
 free fatty acid metabolism, 183
 genetic studies, interpretation
 approaches, 44–5
 lipid metabolism, 97
 lipid storage droplet 2, 183
 long non-coding RNAs, 132
 long-term memory, 45–6
 microRNAs, 132–3
 models
 advantages, 180–1
 for cognitive deficit research,
 183–4
 for cognitive deficits induced by
 sleep deprivation, 180–4
 disadvantages, 180–1
 future research, 51
 for genetic sleep research, 43–51
 results interpretation, 44–6
 for sleep deprivation research, 181
 non-coding RNAs, 132
 Notch signaling, 182–3
 olfactory conditioning, 183
 plasticity, 50–1
 RNA editing, 133
 short-term memory, 45, 182
 sleep, definitional criteria, 43
 sleep homeostasis, 43–4
 sleep regulation, 46–9
 evolutionary conservation, 43
 sleep–wake cycles, 43–4
 starvation studies, 96
 studies, 6–7, 43
 and synaptic homeostasis
 hypothesis, 221
 systems genetics studies, 115–16
- Drosophila* D1 receptor (dDA1), 45,
 181
 expression, 181–2
- Drosophila melanogaster* (fruit fly)
dBTD9 gene, 342–3
 models, 13
 sleep homeostasis, 153
 in sleep research, 105–6, 172
- dSRF* gene, 50
 dual process hypothesis, 208–9
dunce gene, 50
 dystrophia myotonica (DM)
 see myotonic dystrophy
 (MD)
- EGFR (epidermal growth factor
 receptor), gene, 50
 signaling, 48
- egl-4* gene, 58
EHMT1 gene, 133–4
 EIGENSTRAT (software), 8
 electroencephalograms (EEGs)
 astrocyte activity, 85
 humans, 139–40, 148
 mice, 148
 normal sleep, 34
 and sleep genetics, 139–44
 in sleep induction studies, 75
 in sleep studies, 104–5
 electromyograms (EMGs), in sleep
 induction studies, 75
- Elp3* gene, loss of, 132
 emotional memory, 210–11
 emotional salience, and sleep,
 210–11
 energy metabolism enzymes
 and sleep deprivation and
 regulation, 94–9
 energy processing organs, and sleep
 deprivation, 94
 energy status
 determinants, 99
 and sleep–wake regulation, 94
- eNOS* gene, 308
 epidermal growth factor (EGF)
 signaling, 58
 epidermal growth factor receptor
 (EGFR), signaling, 48
 epigenetic marks, readers, 128–9
 epigenetics
 circadian rhythms, 127–36
 factors, 127–31
 field of study, 127
 future research, 135–6
 and gene transcription, 127
 mechanisms, 127–31
 pediatric obstructive sleep apnea,
 307–8
 perspectives, 135–6
 and sleep, 131–3
 sleep disorders, 127–36
 sleep–wake disorders, 133–5
- epilepsy
 familial focal, with variable foci,
 367
 risk factors, 365
 see also nocturnal frontal lobe
 epilepsy (NFLE)
- episodic nocturnal wanderings
 (ENW), 365
- Epworth Sleepiness Scale, 10
 essential hypersomnia (EHS), 237
ETAA1 gene, 342
 ethnic differences, obstructive sleep
 apnea, 279–80
 ethnicity markers, 166–7
 ethyl methane sulfonate (EMS), 49
- European populations, narcolepsy,
 genome-wide association
 studies, 257
 evening preference, delayed sleep
 phase disorder and, 327–8,
 331
 eveningness, 23
 see also morningness–eveningness;
 Morningness–Eveningness
 Questionnaire (MEQ)
- excessive daytime sleepiness (EDS), 260
 and myotonic dystrophy, 266–7
 and symptomatic narcolepsy, 261–2
- executive functions, and sleep
 deprivation, 171–2
 exercise, and muscle fatigue, 219
 explicit memory *see* declarative
 memory
- FABP4* gene, polymorphisms, 307
 false discovery rates (FDRs), 290
 familial advanced sleep phase (FASP)
 animal models, 320–4
 clinical phenotyping, 315–18
 future research, 324–5
 gene discovery, 318–20
 gene therapy, 375
 inheritance, 315
 markers, 314
 molecular mechanisms, 320
 mutations, 318
 trait, 313–15
- familial advanced sleep phase disorder
 (FASPD), 4, 121, 351
 future research, 324–5
 genetics, 23, 313–25
 linkage mapping, 4
 studies, 315–16
- familial aggregation studies, 229–30
 familial focal epilepsy, with variable
 foci, 367
 familial insomnia, 229–30
 see also fatal familial insomnia (FFI)
- familial narcolepsy, prevalence, 235
 familial natural short sleep (FNSS), 23
 familial sleep disorders
 forward genetics, 107–8
 linkage mapping, 4
 familial syndromes, and circadian
 entrainment, 165
- family studies
 autosomal dominant nocturnal
 frontal lobe epilepsy, 368
 electroencephalograms, 140
 restless legs syndrome, 335–44
 sleep genetics, 140
 sleep phenotypes, 1
- FASP* gene, mutations, 319–20
 fatal familial insomnia (FFI), 227, 231

- fatigue, 191
muscle, 219
- fatty acid binding proteins (FABPs), 307
- fatty acids, beta-oxidation, 255
- Fbxl3* gene
and anxiety disorders, 356
mutations, 121
- fear conditioning tests, in sleep deprivation studies, 174
- flies
rover gene, 99
Shaker gene, 107–8
sitter gene, 99
sleep deprivation, 97
wild-type, sleep homeostasis, 43–4
see also Drosophila spp. (fruit flies)
- flip-flop model, 231
- fluid attenuation inversion recovery (FLAIR), 262
- fluoxetine, 353–4
- foraging alleles, *Drosophila* models, 183
- foraging* gene, 98–9, 183
polymorphisms, 46
- forced desynchrony studies, 330
- forme fruste*, use of term, 272
- forward genetic screens
Drosophila models, 49–50, 59
mutant, 49
unbiased, 46, 49
- forward genetics
circadian rhythm studies, 119
familial sleep disorders, 107–8
and reverse genetics compared, 107–8
see also quantitative trait locus (QTL) analysis
- Fos* gene, expression, 75–6, 141, 148, 247
- FOXP3* gene, 134–5
- free fatty acid metabolism, *Drosophila* models, 183
- French-Canadian populations, restless legs syndrome, 337–9
- frequency* gene, feedback loops, 119
- fumin* gene, 44–5
- GABA *see* γ -aminobutyric acid
- GABA-A receptor beta3 subunit, mutations, 231–2
- GABAergic signaling, 211–12
- gabapentin, 335
- Gabra2* gene, 114
- GAL4/UAS system, 46–8
in *Drosophila* models, 180–1
- galanin, 56
- GCaMP, 60–1
- gene co-expression networks, 114
- gene expression
and sleep, 142–3
and sleep deprivation, 153, 219–20
- gene therapy
clinical trials, 375
future research, 379
for sleep disorders, 375–9
- gene transcription
and epigenetics, 127
and long-term memory, 213
- gene transfer, 376–7
future goals, 379
orexin, 378–9
site of, 377–9
- gene translation, and long-term memory, 213
- gene–environment interactions, 104–5, 167–8
- gene–gene interactions, 104–5
- generalized anxiety disorder (GAD), prevalence, 355–6
- genes
oscillating, 122
in sleep–wake regulation, 22–4
see also candidate causal sleep genes (CCSGs); clock genes; metabolic genes; non-metabolic genes
- genetic approaches, complex, 104–6
- genetic control, of circadian pacemaker, 119–23
- genetic disorders
producing symptomatic narcolepsy, 260–8
restless legs syndrome as, 335–7
- genetic epidemiology
arousal disorders, 37–8
insomnias, 36
issues, 39
methods, 33–4
narcolepsy, 37
narcolepsy–cataplexy, 37
obstructive sleep apnea, 36–7
parasomnias, 37–9
restless legs syndrome, 39
sleep, 33–40
sleep disorders, 33–40
future research, 40
issues, 39–40
sleep–wake disorders, 38
- genetic factors
in chronic insomnia, 227–32
chronic insomnia, future research, 232
in insomnias, 230–2
- genetic linkage studies, 13–19
autosomal dominant nocturnal frontal lobe epilepsy, 367–8
- future research, 10
issues, 2
- obstructive sleep apnea, 279–96
future research, 296
methodology, 280–2
results, 284–6
summary, 281
restless legs syndrome, 337–9
see also linkage analysis; linkage mapping
- genetic mapping
animal models, 13–19
inbred strains, 13–14
crosses, 15
outbred strains, 13
- association studies, 1–2
complex traits, 1–2
congenics, 18
high resolution, 18
Mendelian diseases, 1–2
recombinant inbred strains, 15
resources, selection criteria, 18–19
and sequencing, 18
without genotyping
hybrid mouse diversity panel, 17
in silico mapping, 16–17
recombinant congenics and consomics, 16
recombinant inbreds, 15–16
see also linkage mapping
- genetic screens, 59–60
see also forward genetic screens
- genetic sleep research
Drosophila models, 43–51
future trends, 116
quantitative trait locus analysis, 108–11
single-gene approaches, 106–8
systems genetics approaches, 111–12
- genetic variations, and diurnal preferences, 201–2
- genetics
association studies, 13–19
of autosomal dominant nocturnal frontal lobe epilepsy, 365–71
circadian entrainment, 162–8
future research, 168
circadian rhythms, 33–136
delayed sleep phase disorder, 23, 328–9
of familial advanced sleep phase disorder, 313–25
principles, 1–28
of recurrent hypersomnia, 272–6
sleep disorders, 24–7
future research, 27–8
see also sleep genetics

Index

- genome-wide association studies (GWASs), 6–7, 43
 advantages, 23–4, 254
 applications, 284
 association analysis, 8
 circadian entrainment, 166–7
 complex phenotypes, 7
 disadvantages, 254
 genotyping, 7–8
 goals, 7
 insomnia, 25–6
 narcolepsy, 25, 254–8
 narcolepsy–cataplexy, 9
 obstructive sleep apnea, 26–7
 population stratification, 8
 quality control, 8
 replication, 8–9
 restless legs syndrome, 9, 24–5, 43, 335–44
 study characteristics, 340
 sample collection, 7
 sleep, 9
 sleep disorders, 9
 sleep phenotypes, 22–8
 study design, 27
- genomic approaches, complex, 104–6
 genomic imprinting, 131
 and circadian rhythms, 133
 genomic variants, and pediatric sleep-related breathing disorders, 302–8
 genomics, principles, 1–28
 genotype–phenotype interactions, and pediatric sleep-related breathing disorders, 302–8
 genotyping, in genome-wide association studies, 7–8
 genotyping chips, 290–2
GFP-Aequorin transgene, 61
 ghrelin, 92–4
 glia
 classification, 84
 future research, 88
 and neural metabolism, 85
 properties, 85–6
 research issues, 88
 roles, 84, 213–14
 in sleep, 85
 early concepts, 84
 signaling, 84, 213–14
 somnogenic substances, 86
 see also astrocytes; microglia; neurons; oligodendrocytes
 glial cell line-derived neurotrophic factor (GDNF), 304–5
 glial cells see glia
 glial fibrillary acidic protein (GFAP), 86
 glial-derived growth factor (GDGF), 290
 gliotransmission, 86–8
 gliotransmitters, release, 213–14
Glo1 gene, expression, 109
 glucose, 94
 glutamate receptors, modulation, hippocampus and, 177
 glycogen
 roles, 219
 storage, 94
 glycogen–adenosine hypothesis, 96
Gnas gene, expression, 133
gp91phox, 306–7
 green fluorescent protein (GFP), 50–1
 as marker, 321
 growth hormone (GH), and sleep deprivation, 92–3
 growth hormone releasing hormone (GHRH), and sleep deprivation, 92–3
Gsk-3 gene, 355
 GWASs see genome-wide association studies
- halorhodopsin (NpHR), 68
 Hamilton Rating Scale for Depression, 316–17
 HapMap, 166–7
 applications, 284
 HCRT see orexin
 HCRT-2 receptor, mutations, 377
 Hcrt1 peptide, 67
 Hcrt2 peptide, 67
HDAC2 gene, 263
HDAC4 gene, mutations, 133–4
 HDACs see histone deacetylases
 heat shock elements (HSEs), 122–3
 hematopoietic prostaglandin-D synthase (H-PGDS), 75
 inhibitors, 77
 heritability
 in chronic insomnia, 227–32
 definition, 6
 delayed sleep phase disorder, 328
 diurnal preferences, 201, 328
 insomnias, 36
 narcolepsy, 254
 obstructive sleep apnea, 279
 restless legs syndrome, 341
 sleep homeostasis markers, 148–9
 sleep patterns, twin studies, 22
 twin studies, 6, 105–6
 heterogeneity, in insomnia diagnosis, 227–8
 heterogeneous stocks (HSs), 18
 hippocampus, 211–12
 aging and, 214
 and glutamate receptor modulation, 177
 histamine receptors, roles, mice, 141
 histidine decarboxylase (HDC), roles, mice, 141
 histone acetyltransferases (HATs), 129, 131–2
 histone deacetylases (HDACs), 129, 131–2
 inhibitors, 119–21
 histone demethylases (HDMs), 129, 131–2
 histone methyltransferases (HMTs), 129
 histones
 acetylation, 119–21
 modifications, 131–2
 post-translational modifications, 127, 129
 HLA see human leukocyte antigen
 HLA-DQ protein, 239
HLA-DQA1 gene, 235–6
 alleles, 239
HLA-DQA2 gene, 257
HLA-DQB1 gene, 235–8, 263–5
 alleles, 239
 and diseases, 238–9
 and narcolepsy, 254–6
 prevalence, 236
 and recurrent hypersomnia, 274–5
 and symptomatic narcolepsy, 265
 HLA-DR1, and delayed sleep phase disorder, 328–9
HLA-DRB1 gene, 273–4
 and narcolepsy, 254, 257
 polymorphisms, 235–6
*HLA-DRB1*1301-DQB1*0603*
 haplotype, 37, 257
*HLA-DRB1*1501-DQA1*0102-DQB1*0602* haplotype, 235–6
*HLA-DRB1*1501-DQB1*0602*
 haplotype, 254, 256–7
 homeostatic regulation
 and circadian regulation, 147–55
 crosstalk, 151
 future research, 154–5
 research background, 147–8
Homer gene, expression, 219–20
Homer1a gene, 142, 148–9
 expression, 108–9, 148
 roles, 108–9
 hormone levels, and sleep deprivation, 92–3
 Horne–Östberg
 Morningness–Eveningness Questionnaire, 23, 164, 197–8, 316
 familial syndrome studies, 165
 HOX proteins, 341–2
 HPA (hypothalamic–pituitary–adrenal axis), aging and, 215
HSAN1 gene, 263

- HTT* gene, 267–8
- human diurnal preferences
and clock polymorphisms, 197–204
future research, 204
see also time-of-day preferences
- human genome, sequencing, 43
- Human Genome Project, 284
- human leukocyte antigen (HLA)
and autoimmune hypothesis,
237–8
and clinical characteristics, 236–7
disease associations, molecular
mechanisms, 238–9
and diseases, 238–9
and Kleine–Levin syndrome, 274–5
and narcolepsy, 235–9, 254
and recurrent hypersomnia, 274–5
- human susceptibility loci
obstructive sleep apnea, 290
sleep and sleep disorders, 5
- human-based studies, loci, 28
- humans
circadian clock genes, 352
circadian clocks, 163
circadian entrainment, genetics,
163–8
circadian genes, 162
circadian phenotype genetics, 164–6
clock genes, 162–3
and electroencephalograms, 139–40,
148
narcolepsy, 377
sleep deprivation, limitations, 172
sleep genetics, 140
- Huntington's disease (HD)
circadian clock genes and, 358–9
comorbidities, 358–9
disease progression, 358–9
etiology, 267–8
genetics, 2
murine studies, 359
and orexin deficiency, 267–8
penetrance, 3
symptoms, 358–9
- hybrid mouse diversity panel (HMDP),
and genetic mapping
without genotyping, 17
- hyperarousal concept, of insomnias, 231
- hyperekplexia, 266
- hypermethylation, 199
- hypersomnias, 9–10, 235–76
essential, 237
prevalence, 235
see also Kleine–Levin syndrome
(KLS); menstrual-related
hypersomnia (MRH);
recurrent hypersomnia
- hypnotoxins, 73
- hypocretin *see* orexin
- hypocretin deficiency *see* orexin
deficiency
- hypothalamic–pituitary–adrenal axis
(HPA), aging and, 215
- hypothalamic–pituitary–adrenocortical
system, roles, 214
- hypothalamus, and symptomatic
narcolepsy, 261
- ID59699, 264
- identical by descent (IBD), 3–4
- identity by state (IBS), definition, 17
- idiopathic narcolepsy, 260
- IL-1 *see* interleukin-1 (IL-1)
- immediate early genes (IEGs), 143
- imprinting, 179–80
- in silico* mapping, 16–17
- inbred strains, 13–14
backcrossed, 14
chromosomes, 16–17
crosses, 15
intercrossed, 14
phenotype issues, 13–14
see also recombinant inbred strains
(RIs)
- individual differences
circadian regulation, 327
delayed sleep phase disorder, 331
sleep duration, 189–95
overview, 190–1
see also age differences; sex
differences
- influenza, and narcolepsy, 238
- inheritance
diurnal preferences, 199–201
restless legs syndrome, 338–9
- inherited diseases
and cataplexy, 266
and orexin deficiency, 266–8
- inositol triphosphate (IP₃), formation,
84
- Insomnia Severity Index (ISI), 331
- insomniac (inc)* gene, 49–50
- insomnias, 9–10, 227–32
and brain metabolism, 231
characterization, 228
classification, 228
clinical interviews, 228
clock genes and, 26
diagnosis, heterogeneity in, 227–8
disease course, 228
evaluation, issues, 228
genetic epidemiology, 36
genetic factors, 230–2
genome-wide association studies,
25–6
heritability, 36
hyperarousal concept of, 231
pathophysiology, 228
prevalence, 25–6, 227
secondary, 227–8
twin studies, 25–6, 36
see also chronic insomnia; familial
insomnia; primary
insomnias; psychiatric
insomnia
- insufficient sleep, 35
- insulin, and sleep deprivation, 92–3
- interleukin-1 (IL-1), 85
- intermediate and medium
mesopallium (IMM), 179–80
- International Classification of Diseases*
(ICD), sleep disorders,
227–8
- International Classification of*
Sleep Disorders (ICSD),
227–8
insomnias, 228
narcolepsy, 235, 261
recurrent hypersomnia, 272
Second Edition, 24, 243
- International RLS Study Group
(IRLSSG), 335
- ion buffering, astrocytes, 85
- Jackson Laboratory (USA), 13
- Japanese populations, narcolepsy,
genome-wide association
studies, 254–5
- JARID1a (enzyme), 119–21, 131–2
- jet lag disorder, 165
etiology, 327
- JNJ-10397049, 249–50
- KaiA protein, 123
- KaiB protein, 123
- KaiC protein, 123
- Karolinska Sleepiness Scale, 203
- KCNT1* gene, 370–1
- KCTD18* gene, 338
- Kleefstra syndrome, 133–4
- Kleine–Levin syndrome (KLS)
diagnostic criteria, 272
ethnicity, 274
events at onset, 274
familial cases, 273
familial issues, 273–4
future research, 275–6
and human leukocyte antigen,
274–5
monozygotic twin studies, 275
population, 272
twin studies, 274
- knockout (KO) mice
A_{2A} receptor, 76–7
dopamine active transporter, 141
DP₁ receptor, 76–7
in gene transfer studies, 377–8

Index

- knockout (KO) mice (cont.)
 L-PGDS, 76–7
Mbml1, 267
Mbml2, 267
Ptprd, 343–4
 in sleep regulation studies, 76–7
- L-PGDS knockout mice, 76–7
- larks, vs. owls, 197
- late-onset congenital hypoventilation syndrome, 267
- laterodorsal tegmental (LDT) nucleus, 66, 248–9
- LBX1* gene, 342
- learning
 evaluation, 44–5
 mechanisms, 221
 rapid eye movement sleep and, 175
 reinforcement, pathways, 44
 sleep deprivation impacts before, 174–5
- learning impairments, molecular pathways, 181–3
- Leber's congenital amaurosis, 375
- leptin, 92–4
- let-7b* gene, inhibition, 133
- liability threshold model, 5–6
- lifespan, evaluation, 44–5
- light
 bright, 353
 and circadian entrainment, 167–8
 and delayed sleep phase disorder, 331
- light sensitivity, 327–32
- LIN-42* gene, 57–8
- Lingulodinium* spp. (dinoflagellates), circadian entrainment, 162–3
- linkage, use of term, 2
- linkage analysis
 factors affecting, 4
 limitations, 6
 model-free, 3–4, 338
 multipoint, 3–4
 non-parametric, 3–4, 338
 parametric, 3
- linkage disequilibrium, 165–6
- linkage mapping
 approaches, 2–3
 complex phenotypes, 5–6
 early studies, 2
 familial advanced sleep phase disorder, 4
 familial sleep disorders, 4
 narcolepsy-cataplexy, 4
 procedures, 1–2
 restless legs syndrome, 4–5, 337
- linkage studies *see* genetic linkage studies
- lipid metabolism
 roles, 101
 and sleep regulation, 96–7
- lipid storage droplet 2 (LSD2), 97–8
Drosophila models, 183
- lipocalin-type prostaglandin-D synthase (L-PGDS), 75
 inhibitors, 77
- lithium, 355
- loci, human-based studies, 28
- locomotor activity, zebrafish, 56–7
- locus coeruleus (LC), 66–8
- locus coeruleus–norepinephrine (LC–NE) system
 and arousal control, optogenetic dissection, 68–70
 dynamics, 70–1
- logarithm of odds (LOD) scores, 14, 280–2, 284–6, 304
 determination, 3
 values, 3
- long non-coding RNAs (lncRNAs)
Drosophila studies, 132
 mechanisms, 130
 roles, 130
- long sleepers, 190–1
- long-term memory (LTM)
 consolidation, 211
 definition, 208
Drosophila models, 45–6
 evaluation, 44–5
 and gene transcription, 213
 and gene translation, 213
 induction, 51
 mechanisms, 212
 other, 214
see also declarative memory; procedural memory
- long-term memory storage
 and sleep, 208–16
 future research, 216
- long-term potentiation (LTP), 177
- LPAR1* gene, 27, 290–2
- Lsd2* gene, 97–8
 mutations, 98, 183
- lymphoid tissue growth, and pediatric obstructive sleep apnea, 302–3
- macrophage migration inhibitory factor (MIF), 307
- major depressive disorder (MDD)
 animal models, 353–4
 circadian clock genes and, 353–4
 DNA methylation, 134–5
 genetics, 26
 prevalence, 353
 treatment, 353
- major histocompatibility complex (MHC) *see* human leukocyte antigen (HLA)
 and sleep, 171, 211–14
 and sleep deprivation, 212–13
 and slow-wave sleep, 211–12
see also long-term memory storage
 manic-depressive disorder *see* bipolar disorder (BPD)
- Maoa* gene, 355
- MAP2K5* gene, and restless legs syndrome, 339, 342
- MAP2K5/LBXCOR1* gene, 9, 24
- Markov models, hidden, 18
- maze tasks, 211–12
- Mbml1* knockout mice, 267
- Mbml2* knockout mice, 267
- medical disorders, 351–71
- medication effects, 375–9
- meiosis, and recombination, 2
- MEIS1* gene, 9, 24
 and restless legs syndrome, 339, 341–2
- Meis1* gene, 341–2
- melanin-concentrating hormone (MCH), 56, 66
- melanopsin, 122
- melatonin, 199, 331
 and delayed sleep phase disorder, 328, 330–1
 and memory consolidation, 214–15
 and Parkinson's disease, 216
 sleep induction, 56
- memory
 acquisition, 208
 and aging, 214–15
 and brain regions, 209
 consolidation, 208
 retrieval, 208
 early studies, 208
 evaluation, 44–5
 mechanisms, 171
 pathways, 44
 and plasticity, 50
 and sleep
 early studies, 208
 future research, 216
 impacts, 208–11
 rapid eye movement sleep and, 177–8
 sleep and, 45–6, 51, 208–9
 sleep deprivation and, 175
 slow-wave sleep and, 177–8
 stages, 208
 storage
 and sleep, 171, 211–14
 and sleep deprivation, 212–13
 and slow-wave sleep, 211–12
see also long-term memory storage
 types of, 208
 two-stage model, 209
 working, 208

- see also* declarative memory;
emotional memory;
long-term memory (LTM);
procedural memory;
short-term memory
- Mendelian diseases, 1–2
- menstrual-related hypersomnia (MRH), 272–4
- mental retardation, 360
- metabolic abnormalities, in
narcolepsy, 249
dysfunction, in pediatric obstructive
sleep apnea, 307
- metabolic endocrine system, and sleep
regulation, 92–4
- genes
in sleep regulation, 91–101
future research, 101
transcripts, 94
syndrome, 91
- metabolism
brain, 231
free fatty acids, 183
hypotheses, early, 91–2
neural, 85
non-metabolic genes and, 99–101
and sleep deprivation, 92
see also energy metabolism
enzymes; lipid metabolism
- metabolism–sleep interactions, 91
- metabotropic glutamate receptors (mGluR), activation, 84
- methyl-CpG-binding domain (MBD), 128–9
- methyl-CpG-binding domain
protein 2 (MECP2), 128–9
- N-methyl-D-aspartate receptors (NMDARs)
expression, 154
mechanisms, 150
modulation, 177
roles, 150
- methylation, 199
see also DNA hydroxymethylation;
DNA methylation
- MHC *see* human leukocyte antigen (HLA)
- mice
adenosine, roles, 141–2
alpha-synuclein overexpressing, 358
Btd9 gene, 343
BXD RI, 108–9, 142
Clock mutant, 100, 354–5
db/db, 93
diversity outbred, 111
and electroencephalograms, 148
GABA receptors, 141
histamine receptors, roles, 141
Huntington's disease studies, 359
- leptin deficiency, 93
Mecp2 deficient, 131
Meis1 gene, 341–2
myotonic dystrophy studies, 267
narcolepsy models, 243, 377
non-rapid eye movement, 142
ob/ob, 93
Orexin, 244–6
orexin, roles, 141
outbred strains, 18
Parkinson's disease studies, 358
R6/2, 359
Rai1 mutant, 360
rapid eye movement sleep, 142
reverse genetics, 140
serotonin, roles, 141
sleep deprivation studies, 153–4,
172–3
sleep genetics, 140–2
slow-wave activity, 148–9
strains, sequencing variants, 18
systems genetics studies, 114–15
wheel-running behavior, 321
see also knockout (KO) mice; *Mus musculus* (house mouse);
transgenic mice
- microarray studies
sleep, and gene expression, 142–3
and systems genetics compared,
111–12
wakefulness, 143
- microglia
roles, 84
somnogenic substances, secretion,
87–8
- microRNAs (miRNAs), 130
Drosophila studies, 132–3
and sleep, 133
- mid-phase of sleep on free days (MSF), 164
regional differences, 167
- migration
birds, 98
cognitive function maintenance,
180
- miniature excitatory postsynaptic
currents (mEPSCs), 221
- minisleep* (*mns*) gene, 49
- minocycline, roles, 87–8
- miR-132* gene, 132–3
- miR-138* gene, inhibition, 133
- miR-219* gene, expression, 132–3
- miRNAs *see* microRNAs
- MK-4305 (Suvorexant), 249
- Möbius syndrome, 266
- model organisms
circadian clocks, 162–3
in sleep genetics, 13–19
see also animal models
- monozygotic (MZ) twins
chronic insomnia studies, 227, 229
diurnal type studies, 34
electroencephalograms, 139–40
heritability, 6, 105–6
insomnia studies, 36
Kleine–Levin syndrome studies,
275
narcolepsy studies, 237
restless legs syndrome studies, 336
sleep genetics, 140
sleep length studies, 34–5
sleep quality studies, 35
variability studies, 33
- mood disorders
circadian clock genes and, 26, 353–5
etiologies, 355
see also depressive disorders
- morningness, 23
- morningness–eveningness, twin
studies, 23, 34
- Morningness–Eveningness
Questionnaire (MEQ),
197–8
applications, 164
limitations, 198
see also Horne–Östberg
Morningness–Eveningness
Questionnaire
- Morris water maze, 174
- multiple sclerosis (MS), 262
- multiple sleep latency test (MSLT),
236, 267
in symptomatic narcolepsy, 261
- multiple sleep–wake traits
genetics
future trends, 116
systems biology approaches,
104–16
- Munich ChronoType Questionnaire (MCTQ), 164, 316
development, 198
diurnal preference studies,
199, 203
familial syndrome studies, 165
- Mus musculus* (house mouse), 15–16
- Mus musculus domesticus* (house
mouse subspecies), 18
- muscle fatigue, and exercise, 219
- mushroom bodies (MBs), 45–8
in learning studies, 181
- mutagenesis screens, 107–8
- myelin oligodendrocyte glycoprotein (MOG), and narcolepsy, 258
- myotonic dystrophy (MD), 266–7
- nAChRs (nicotinic acetylcholine
receptors), 370–1
- Nampt* gene, expression, 123

Index

- narcolepsy, 235–76
 age of onset, 238
 animal models, 25, 243, 260, 377
 characterization, 235, 243
 etiology, 37
 familial, prevalence, 235
 future research, 237, 257
 gene therapy, 375–6
 genetic epidemiology, 37
 genome-wide association studies, 25, 254–8
 Caucasian populations, 255–7
 European populations, 257
 future research, 258
 issues, 257–8
 Japanese populations, 254–5
 heritability, 254
 human, 377
 and human leukocyte antigen, 235–9, 254
 incidence, 238
 and influenza, 238
 metabolic abnormalities, 249
 murine models, 243, 377
 and orexin, 25, 67, 236–7, 242–51, 376
 future research, 251
 mechanisms, 243–4
 and orexin deficiency, 242, 244–9
 and orexin neurons, 237
 and orexin-A, 244
 pathogenesis, 254
 pathophysiology, 247–8
 prevalence, 243, 260
 risk factors, 237
 symptoms, 4, 37, 235, 237, 260
 triggers, 238
 use of term, 235
see also autosomal dominant cerebellar ataxia, deafness and narcolepsy (ADCA-DN); idiopathic narcolepsy; secondary narcolepsy; symptomatic narcolepsy
- narcolepsy–cataplexy, 1, 4, 260
 association studies, 9
 definition, 4, 235, 261
 genetic epidemiology, 37
 genome-wide association studies, 9
 linkage mapping, 4
 and orexin, 236–7
 pathophysiology, 246
 treatment, 250
- narcoleptoid personality traits, 237
Narp gene, 219–20
 natural short sleeper (NSS), 23
Ncor2 gene, roles, 112–14
 ncRNAs *see* non-coding RNAs
 nematodes
 in sleep research, 54–62
 see also Caenorhabditis elegans (nematode)
- neural metabolism, and glia, 85
 neurobiological traits, sleep duration as, 192–3
 neurodegenerative diseases, 215
 dementia associated with, circadian clock genes and, 357–9
 diagnostic criteria, 215
 gene therapy, 375
 neurodevelopmental disorders, etiology, 133–4
 neuroglia *see* glia
 neuromodulators, signaling, 56
 neuromuscular reflexes, and pediatric obstructive sleep apnea, 302–4
 neuromyelitis optica (NMO), 261–2
 neuronal per-arnt-sim protein 2 (NPAS2), 99
 neuronal replays, and sleep, rodents, 175–6
- neurons
 arousal, optogenetic control of, 66–71
 cholinergic, 66, 211–12
 dopamine expressing, 48–9
 expression, 48
 noradrenergic, 141
 octopamine expressing, 48
 orexin-producing, 242
 roles, 104–5
 in sleep regulation, 56
 in sleep–wake cycles, 66
 ventral lateral, 48, 50–1
see also glia; orexin neurons
- neuropeptide S (NPS), 66–7
 neuropeptide Y (NPY), increase, 99
Neurospora crassa (fungus)
 circadian entrainment studies, 163
 frequency gene, 119
 neurotransmitters, roles, 140–1
 neurotrophins, 84
 secretion, 85
NGFI-A gene, expression, 219–20
 nicotinamide adenine dinucleotide phosphate (NADPH), 306–7
 nicotine, 211–12
 nicotinic acetylcholine receptors (nAChRs), 370–1
 Niemann–Pick type C (NPC) disease, 265–6
 nightmares, twin studies, 38
 nitric oxide, secretion, 87–8
 NMDARs *see* N-methyl-d-aspartate receptors
 nocturnal frontal lobe epilepsy (NFLE), 365–7
 seizures, 371
 see also autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
- nocturnal paroxysmal dystonia (NPD), 365–7
 non-coding RNAs (ncRNAs)
 and circadian rhythms, 132–3
 classification, 130
Drosophila studies, 132
 expression, 130, 132
 regulation, 127, 129–30
 roles, 129–30
see also long non-coding RNAs (lncRNAs)
- non-declarative memory, 210
 non-metabolic genes, 99–101
 non-rapid eye movement sleep (NREMS), 66, 85, 93, 133, 199–201
 delta waves, 105
 induction, 75–6
 mice, 142
 orexin and, 247
 and sleep duration, 190
 stages, 104–5, 139, 208–9
 and synaptic consolidation, 220
 see also slow-wave sleep (SWS)
- noradrenergic (NA) neurons, lesions, 141
 norepinephrine (NE), and arousal, 67–8
- normal sleep
 electroencephalograms, 34
 genetic epidemiology, 34–5, 39
 polysomnography, 34
 Norrie disease (ND), 266
NOS1 gene, 337–8
Notch gene, signaling, 58
 Notch signaling, *Drosophila* models, 182–3
NPAS2^{-/-} mice, 99
 NPC disease *see* Niemann–Pick type C disease
NPC1 gene, mutations, 265
Nr1d1 gene, activation, 353–4
NRIF2 gene
 and schizophrenia, 357
 inhibition, 353–4
Ntsr1 gene, 114
 nucleosomes, 119–21
 nucleus accumbens (NAc), shell, 78
- ob/ob* mice, 93
 obesity
 and obstructive sleep apnea, 26–7
 and pediatric obstructive sleep apnea, 307
 risk factors, 279–80

- single nucleotide polymorphisms, 279–80
susceptibility loci, 287
- object recognition tasks, 174
- obsessive–compulsive disorder (OCD), prevalence, 355–6
- obstructive sleep apnea (OSA), 9–10
African American populations, 284–6
age of onset, 26–7
association studies, 282–4
and body mass index, 284–6, 292
candidate gene studies, 27, 279–96
future research, 296
no associations, 285
results, 286–96
cardiovascular outcomes, 288
Caucasian populations, 284–6
comorbidities, 296
consequences, 279, 291–6
and diabetes type 2, 293
DNA methylation, 134–5
ethnic differences, 279–80
etiology, 26–7, 279
gene therapy, 375
genetic epidemiology, 36–7
genetic linkage studies, 279–96
future research, 296
methodology, 280–2
results, 284–6
summary, 281
genetics, 279
approaches, 280–4
genome-wide association studies, 26–7
heritability, 279
human susceptibility loci, 290
inherited abnormalities, 292
and obesity, 26–7
phenotypic factors, 27
prevalence, 26–7, 279
risk factors, 26–7, 279–80
severity, 305
symptoms, 26–7, 36–7
treatment, 296
see also pediatric obstructive sleep apnea (POSA)
- octopamine expressing neurons, 48
- olfactory conditioning, *Drosophila* models, 183
- oligodendrocytes
roles, 84
somnogenic substances, secretion, 87–8
- ONO-4127Na, 77
- opioidergic drugs, 335
- Opn4* gene, 122
- optogenetic control, of arousal neurons, 66–71
- optogenetic dissection, and arousal control, 68–70
- optogenetic manipulation, of sleep neural circuit, 61
- optogenetics
actuators, 68
field of study, 68
future research, 71
rodent models, 172–3
- orexin, 56–7
and arousal control, optogenetic dissection, 68–70
deficiency, 263
dynamics, 70–1
expression, 57, 66
future research, 251
gene transfer, 378–9
and Huntington's disease, 267–8
and inherited diseases, 266–8
mechanisms, 243–4
mice, 244–6
and myotonic dystrophy, 266–7
and narcolepsy, 25, 67, 236–7, 242–51, 376
and Niemann–Pick type C disease, 265–6
and Prader–Willi syndrome, 265
roles, 99, 247–8
mice, 141
in sleep–wake cycles, 107–8
and symptomatic narcolepsy, 261–2
and wakefulness, 67, 249
- orexin neurons, 67, 242, 377–8
connections, 245
efferents, 246–7
localization, 242
and narcolepsy, 237
projections, 376
regulatory mechanisms, 244–6
- orexin neuropeptide system, 242
- orexin receptor antagonists, 249–50
- orexin receptor type 2 (Ox2R), 25
- orexin receptors, 242
drugs targeting, 249–50
subtypes, 247–9
- orexin-1 (OXR-1) receptor, 242
- orexin-2 (OXR-2) receptor, 242
- orexin-A, 248, 250
identification, 242
and narcolepsy, 244
- orexin-B, 248
identification, 242
- orexin/ataxin-3* transgenic mice, 244–6, 250, 378–9
- orexinergic activity, in sleep–wake cycles, 247
- oscillating genes, 122
- oscillators
peripheral, 351–3
transcription/translation, 120
- OSM-7* gene, 58
- OSM-11* gene, 58
- outbred strains, 13, 18
- owls, vs. larks, 197
- oxidative stress, and pediatric obstructive sleep apnea, 306–7
- Oxr-1* gene, 242, 246
expression, 248–9
roles, 249
- Oxr-2* gene, 242, 246
expression, 248
mutations, 243
roles, 249
- oxytocin, 56
- P2RY11* gene, 9, 25, 268
and narcolepsy, 256–7
and symptomatic narcolepsy, 263
- P2X7* receptor, 94–6
- P2Y11* gene, 243–4
- p22phox*, 306–7
- panic disorder, prevalence, 355–6
- parasomnias, 38, 335–44
definition, 37
genetic bases, common, 38–9
genetic epidemiology, 37–9
and nocturnal frontal lobe epilepsy, 366
and rapid eye movement sleep, 38
twin studies, 38–9
- Parkinson's disease (PD), 216, 358
- paroxysmal arousals (PAs), 365
- paroxysmal kinesigenic dyskinesia (PKD), 367
- pars intercerebralis*, 48
- PBX proteins, 341–2
- PCEK* gene, 290–2
- PDE4D* gene, 10
- Pebp1* gene, roles, 114
- pediatric autoimmune neuropsychiatric disorders associated with *Streptococcus* (PANDAS), 238
- pediatric obstructive sleep apnea (POSA), 302
African American populations, 304
anatomical factors, 302–3
Caucasian populations, 304
and cognitive function, 306–7
comorbidities, 305
craniofacial factors, 302–3
epigenetic modifications, 307–8
future research, 308
genetic determinants of end-organ susceptibility, 305–8

Index

- pediatric obstructive sleep apnea (POSA) (cont.)
 genetics, 304–5
 and lymphoid tissue growth, 302–3
 metabolic dysfunction in, 307
 morbidity risks, 307–8
 and neuromuscular reflexes, 302–4
 and obesity, 307
 and oxidative stress, 306–7
 pathophysiological mechanisms, 302–4
 risk factors, 304–5
 and upper airway inflammation, 302–3
 and uric acid, 306
- pedigrees, 3
 restless legs syndrome, 337–8
 studies, 282–4
- pedunculopontine nucleus (PPN), 66
 pedunculopontine tegmental nucleus (PPT), 246, 248–9
- penetrance, 3
- pentobarbital, sleep induction, 56
- per* gene *see* *Period* gene
- PER1* gene, 134–5, 328–9, 351
 and Alzheimer's disease, 357–8
 and diurnal preferences, 202
 expression, 353
 polymorphisms, 23
- Per1* gene, 22, 119–22, 131, 150, 351
 absence of, 153–4
 and anxiety disorders, 356
 expression, 107, 151–2, 359
 inhibition, 353–4
- PER2* gene, 134–5, 320
 and Alzheimer's disease, 357–8
 deregulation, 360
 and diurnal preferences, 202
 expression, 359
 mutations, 319–20
 phenotypes, 323
 polymorphisms, 23
 and seasonal affective disorder, 354
- Per2* gene, 4, 22, 119–22, 150, 321–4
 absence of, 153–4
 binding, 152–3
 expression, 107, 151–2, 359
 mutations, 23
 variants, 123
- PER2* transgenic mice, 321–4
 circadian phenotypes, 322
- PER3* gene, 10, 134–5, 232
 and borderline personality disorder, 359–60
 and delayed sleep phase disorder, 328–31, 331
 deregulation, 360
 and diurnal preferences, 200, 202–3
- polymorphisms, 23, 154, 194, 202, 329–30
 tandem repeats, 329–30
 roles, 154
 non-circadian, 202–3
 and schizophrenia, 357
 and sleep homeostasis, 203
- Per3* gene, 22, 119–21
 expression, 154
 polymorphisms, 107
 studies, 26
- Period* gene, 22, 50, 57–8
 mutations, 49, 119
 roles, 119
 transcription, 122
- PERIOD3* gene, 171–2
- periodic limb movements (PLMs), 335
 gene therapy, 375
 in sleep, 339
- peripheral blood mononuclear cells (PBMCs), 256–7
 oscillators, 351–3
- peripheral clocks, 123
- personality disorders
 circadian clock genes and, 359–60
see also borderline personality disorder (BLPD)
- pharmacology, reverse, 242
- phase response curves (PRCs), 328
- phosphatidylcholine, biosynthesis, 255
- photoperiods, and circadian entrainment, 168
- physiological activity, during sleep, 60–1
- piggyBac* gene, 49–50
- pigment dispersing factor (PDF), 48
- Pittsburg Sleep Questionnaire Inventory, 230
- plasticity, 50–1
- PLEK* gene, 27
- polysomnography (PSG), normal sleep, 34
- population stratification, in genome-wide association studies, 8
- post-translational modifications (PTMs), histones, 127, 129
- post-traumatic stress disorder (PTSD), prevalence, 355–6
- Prader–Willi syndrome (PWS)
 genetics, 263–5
 orexin and, 265
 and symptomatic narcolepsy, 263–5
 symptoms, 133–4, 263–5
- pre-miR-182* gene, 134
- pregabalin, 335
- prepro-orexin* gene, 242–3
 mutations, 260
- primary insomnias, 227–30
 genetics, 230
 molecular studies, 231–2
 vs. psychiatric insomnia, 231
- principal components analysis (PCA), applications, 8
- prion protein, abnormal, 231
- procedural memory, 210
 consolidation, 214–15
- PROKR2* gene, 353
- proopiomelanocortin, 56
- prostaglandin D₂ (PGD₂)
 adenosine system, in human sleep, 78–80
 in physiological sleep, 77
 receptors, in central nervous system, 75
 secretion, 87–8
 in sleep induction, 73–6
 in sleep regulation, 73–80
 early studies, 73–5
 future research, 80
 synthase, in central nervous system, 75
- prostaglandin-D synthase (PGDS)
 classification, 75
 inhibitors, 77
- prostaglandins (PGs)
 biosynthesis, 73–4
 discovery, 73
 secretion, 85, 87–8
- protein kinase A (PKA)
 activity, 46–8
 signaling, 44, 58
- protein kinase G (PKG), 98–9
- PRP* gene, mutations, 231
- PRRT2* gene, 367
- psychiatric disorders, 351–71
 adolescents, and delayed sleep phase disorder, 327–8
 circadian clock genes and, 351–60
 future research, 360
 mechanisms, 359–60
- psychiatric insomnia, 229–30
 vs. primary insomnias, 231
- psychovigilance task, 174–5
- psychomotor vigilance tasks (PVTs), 191
 variance, 193
- PTGER3* gene, 27, 290–2
- PTPRD* gene, 9, 24–5, 339–41
 and restless legs syndrome, 343–4
- Ptprd* knockout mice, 343–4
- PWS *see* Prader–Willi syndrome
- quality control, in genome-wide association studies, 8
- quantitative trait locus (QTL) analysis
 advantages, 110–11
 applications, 106–8

- definition, 108
early studies, 108
future research, 111
genetic factors, 109–10
in genetic sleep research, 108–11
limitations, 111
sleep genetics, 110
mice, 142
and systems genetics, 111–12
quantitative trait locus (QTL)
mapping, 18
approaches, 14
confidence intervals, 14
issues, 17
multiple linked, 15
significance thresholds, 14
- R6/2 mice, 359
racial admixtures, effects, 165–6
Raii gene
mutations, 360
reduced expression, 133–4
Rai1 mutant mice, 360
rapid eye movement (REM),
abnormal, 4
rapid eye movement sleep (REMS), 66,
208–9
aging and, 215
characterization, 139
and emotional memory, 211
and learning, 175
and memory consolidation, 177–8
mice, 142
orexin and, 247
and parasomnias, 38
and procedural memory, 210
regulation, 96–7
rodents, 173–4
roles, 220
stages, 104–5
see also non-rapid eye movement
sleep (NREMS); REM sleep
deprivation (RSD)
- Rarb* gene
expression, 109
polymorphisms, 148–9
roles, 109, 142
- rats
narcolepsy models, 377
outbred strains, 18
sleep deprivation studies, 172–3
Rca1 gene, 50
reciprocal-interaction models, 67
recombinant
adeno-associated virus (rAAV), 378–9
congenics, and genetic mapping
without genotyping, 16
consomics, and genetic mapping
without genotyping, 16
- inbred strains (RIs), 15–16
creation, 15
phenotyping, 15
systems genetics studies, 115–16
recombination, 2
recurrent hypersomnia
autoimmunity, 275
diagnostic criteria, 272
early studies, 272
ethnicity, 274
events at onset, 274, 276
familial issues, 273–4
future research, 275–6
genetics, 272–6
and human leukocyte antigen, 274–5
population, 272
twin studies, 274
use of term, 272
see also Kleine–Levin syndrome
(KLS); menstrual-related
hypersomnia (MRH)
- REM sleep deprivation (RSD), 173–5
replication, in genome-wide
association studies, 8–9
resistance to dieldrin (RDL), 48
respiratory disturbance index (RDI), 27
restless legs syndrome (RLS), 1, 4
age differences, 335
and *BTBD9* gene, 342–3
candidate gene studies, 339
comorbidities, 335–6
diagnostic criteria, 335
early studies, 335
familial, 336–7
family studies, 335–44
heterogeneity and complexity,
338
French-Canadian populations,
337–9
future research, 344
gene therapy, 375
as genetic disorder, 335–7
genetic epidemiology, 39
genetic linkage studies, 337–9
genome-wide association studies, 9,
24–5, 43, 335–44
characteristics, 340
follow-ups, 341–4
overview, 339–41
heritability, 341
inheritance, 338–9
linkage mapping, 4–5, 337
and *MAP2K5* gene, 339, 342
and *MEIS1* gene, 339, 341–2
origin of term, 335
over-dominance in, 339
pedigrees, 337–8
prevalence, 335
and *PTPRD* gene, 343–4
- sex differences, 335
and *SKOR1* gene, 342
symptoms, 4–5, 335–7
and *TOX3* gene, 343
treatment, 335
twin studies, 39, 336
restriction fragment length
polymorphisms (RFLPs), 2
retinoic-acid-related orphan receptor
response element (RORE)
sequences, 121, 123
Rett syndrome, etiology, 133–4
Rev-Erb genes, 123, 150
overexpression, 122
roles, 121
reverse genetics
applications, 162
circadian rhythm studies, 119
and forward genetics compared,
107–8
mice, 140
zebrafish, 60
reverse pharmacology, 242
RHO protein, 48
RLS *see* restless legs syndrome
RLS genetic loci, 338–41
RNA
editing, 127, 130–1
and circadian rhythms, 133
interference, 59
see also microRNAs (miRNAs);
non-coding RNAs
(ncRNAs)
RNA binding proteins (RBPs), 130
RNA-induced silencing complex
(RISC), 130
robust nucleus of arcopallium (RA),
and song learning, 178–9
rodent models, 172–3
for cognitive deficits induced by
sleep deprivation, 172–8
rodents
circadian clock genes, 351
rapid eye movement sleep, 173–4
REM sleep deprivation, 173–4
sleep, and neuronal replays, 175–6
sleep deprivation, and cognition,
174–5
sleep deprivation protocols, 173–4
sleep deprivation studies, cognitive
tasks, 174
suprachiasmatic nucleus studies,
151
total sleep deprivation, 173–4
see also mice; rats
rolipram, 212–13
Rors gene, 150
roundworms
in sleep research, 54–62

Index

- roundworms (cont.)
 see also *Caenorhabditis elegans*
 (nematode)
 rover gene, 98–9
 RPE65 gene, 375
 rs1154155, 255–7
 rs2305795, 256
 rs2858884, 257
 rs4804122, 256
 rs5770917, 254–5
 rutabaga gene, 50, 183
- SAM (S-adenosyl methionine), 128–9
- sample collection, in genome-wide association studies, 7
- SB-408124, 249–50
- schizophrenia, 356–7
- seasonal affective disorder (SAD), 122
 circadian clock genes and, 354
 prevalence, 354
 symptoms, 354
- secondary narcolepsy
 use of term, 260–1
 see also symptomatic narcolepsy
- seizures, 371
 classification, 365
- selective serotonin reuptake inhibitors (SSRIs), 353–4
- selenium compounds, 77
- sensory gating, mechanisms, 58–9
- sequencing
 animal models, 43
 and genetic mapping, 18
- sequential hypothesis, 177–8
- serotonin
 roles, 106–7
 mice, 141
 transporter length polymorphism, 232
- serum response factor (SRF), 50
- sex differences
 diurnal preferences, 199
 restless legs syndrome, 335
- Shaker* gene, 49
 identification, 107–8
 mutations, 49–50
- sharp-wave ripples (SWRs), 175–6
- shibire* gene, 46–8
- shift work sleep disorder (SWSD),
 etiology, 327
- short sleepers, 190, 190–2
- short-term memory
 definition, 208
Drosophila models, 45, 182
 evaluation, 44–5
- single cells, clock research, 163
- single nucleotide polymorphisms (SNPs), 15–16
 adenosine deaminase studies, 80
 common, 7
 in linkage mapping, 2–3
 in obesity, 279–80
 single nucleotide variants (SNVs), 254–6
 single-gene approaches, 106–8
Sirt1 gene, expression, 123
 SIRT1 protein, roles, 131–2
sitter gene, 98–9
SKOR1 gene, 339
 and restless legs syndrome, 342
 Skp1–Cullin–F-box (SCF) complex, 121
- sleep
 in A_{2A} receptor KO mice, 76–7
 benefits, 208
 characterization, 139
 and circadian clock genes, humans, 351–3
 circadian regulation, and
 homeostatic regulation, 147–55
 definitional criteria, 43
 in DP1 receptor KO mice, 76–7
 and emotional salience, 210–11
 and epigenetics, 131–3
 functions, 50–1, 139
 and brain, 219
 future research, 61
 and synaptic plasticity, 219–20
 theories, 85
 and gene expression, 142–3
 genetic bases
 linkage and candidate gene studies, 279–96
 modeling, 13–19
 genetic epidemiology, 33–40
 genome-wide association studies, 9
 glial roles, early concepts, 84
 homeostatic regulation, and
 circadian regulation, 147–55
 human susceptibility loci, 5
 hypotheses, animal models, 91–2
 inadequate, 91–3
 in L-PGDS KO mice, 76–7
 and long-term memory storage, 208–16
 future research, 216
 and memory
 early studies, 208
 future research, 216
 impacts, 208–11
 and memory consolidation, 45–6, 51, 208–9
 and memory storage, 171, 211–14
 and microRNAs, 133
 and neuronal replays, rodents, 175–6
 physiological, prostaglandin D₂ in, 77
 physiological activity during, 60–1
 physiology, 139–223
 and procedural memory, 210
 prostaglandin D₂–adenosine system in, 78–80
 as quantitative trait, 10
 spontaneous, 50–1
 stages, 104–5, 208–9
 studies, behavioral approaches, 54
 and synaptic homeostasis, 219–23
 synaptic homeostasis theory of, 177–8
 see also normal sleep; rapid eye movement sleep (REMS); slow-wave sleep (SWS)
- sleep apnea
 genetics, 26–7
 see also obstructive sleep apnea (OSA)
- sleep architecture, aging and, 214
- sleep bruxism, twin studies, 38
- sleep deprivation (SD), 50–1
 animal models, 211
 limitations, 172
 bird models, 178
 and cognition, rodents, 174–5
 cognitive deficits, 171, 193
 animal models, 171–84
 bird models, 178–80
Drosophila models, 180–4
 future research, 184
 individual differences, 193
 mechanisms, 177–8
 rodent models, 172–8
 and cognitive tests, 171–2
 rodents, 174
 and delayed sleep phase disorder, 330
Drosophila models, 181
 energy metabolism enzymes and, 94–9
 and energy processing organs, 94
 and executive functions, 171–2
 flies, 97
 and gene expression, 153, 219–20
 and ghrelin, 92–3
 and hormone levels, 92–3
 humans, limitations, 172
 impacts, before learning, 174–5
 and imprinting, 179
 individual differences, 171–2
 and memory consolidation, 175
 and memory storage, 212–13
 and metabolism, 92
 mice, 153–4
 performance impairment, 192
 protective mechanisms, 98

- protocols, rodents, 173–4
short sleepers, 191
in sleep homeostasis studies, 148–9
and sleep pressure, 151–3
twin studies, 194
see also REM sleep deprivation (RSD); sleep loss; total sleep deprivation (TSD)
- sleep disorders
and abnormal sleep, 35–9
classification, 24, 227–8
as dichotomous traits, 9–10
epigenetics, 127–36
gene therapy, 375–9
genetic bases, linkage and candidate gene studies, 279–96
genetic epidemiology, 33–40
future research, 40
issues, 39–40
genetics, 24–7
future research, 27–8
genome-wide association studies, 9
human susceptibility loci, 5
primary, 4
and sleepiness, 35–9
twin studies, 33
variability, 33
see also circadian rhythm sleep disorders (CRSDs); familial sleep disorders
- sleep disturbances, caffeine-induced, 107
- sleep duration
and bipolar disorder, 354
and body mass index, 92
and brain size, 91–2
and diurnal preferences, 199
and cognitive deficits, 191
individual differences, 189–95
issues, 194–5
overview, 190–1
as neurobiological trait, 192–3
sleep enuresis, twin studies, 38
- sleep genetics
and electroencephalograms, 139–44
future research, 143–4
family studies, 140
humans, 140
mice, 140–2
model organisms, 162–3
overview, 139
quantitative trait locus analysis, 110
mice, 142
- Sleep Heart Health Study, 27
- sleep history, prior, roles, 191
- sleep homeostasis, 66, 70, 105, 327–32, 139–223
allostatic changes, 191–2
and clock gene mutations, 153–4
- Drosophila* models, 43–4
dynamics, variations, 149
long sleepers, 190–1
markers, 327–8
heritability, 148–9
mechanisms, 189–90
and *PER3* gene, 203
short sleepers, 190–1
and synaptic functions, 149–50
see also synaptic homeostasis hypothesis (SHY)
- sleep induction
mechanisms, 73
prostaglandin D₂ in, 73–5
molecular mechanisms, 75–6
- sleep intensity, and delta waves, 105
- sleep length, 34–5
- sleep loss
differential vulnerability, 193–4
metabolic cost, 219
responses
individual differences, 189–95
future issues, 194–5
see also sleep deprivation (SD)
- sleep mechanisms, animal models, 43
- sleep need, determinants, 220
- sleep neural circuit, optogenetic manipulation, 61
- sleep patterns, heritability, twin studies, 22
- sleep phenotypes
complex, 1
family studies, 1
genome-wide association studies, 22–8
heritability, 1
multiple, 105
twin studies, 1
see also complex phenotypes
- sleep pressure, 151–3
homeostatic, 327
markers, 149
- sleep problems, twin studies, 35–6
- sleep quality, twin studies, 35
- sleep regulation
adenosine in, 77–8, 95, 107
astroglial, 84–8
Drosophila models, 46–9
energy metabolism enzymes and, 94–9
genetics, 43
hypotheses, 91
and lipid metabolism, 96–7
long sleepers, 190
metabolic endocrine system and, 92–4
metabolic genes in, 91–101
future research, 101
- models, 147–8
two-process, 189–90
neurons in, 56
non-metabolic genes and, 99–101
processes, interactions and independence, 151
prostaglandin D₂ in, 73–80
future research, 80
short sleepers, 190
see also circadian regulation; homeostatic regulation
- sleep research
animal models, 54–5, 105–6, 172
and memory, 208–9
Caenorhabditis elegans in, 54–62
early, 147
future trends, 116
zebrafish in, 54–62, 184
see also genetic sleep research
- sleep restriction, protocols, 92
- sleep schedules
assessment, 316
markers, 149
- sleep terrors, twin studies, 37–8
- sleep times *see* sleep duration
- sleep timing
and sleep homeostasis dynamics variations, 149
see also sleep–wake timing
- sleep-like states, occurrence, 66
- sleep-onset rapid eye movement periods (SOREMPs), 263–5
and myotonic dystrophy, 266–7
- sleep-related breathing disorders, 279–308
pediatric
genomic variants, 302–8
genotype–phenotype interactions, 302–8
movement disorders, 335–44
- sleep–wake cycles
and circadian rhythms, 351
determinants, 327
Drosophila models, 43–4
evolutionary conservation, 66
future research, 104
neurons in, 66
orexiner activity in, 247
reciprocal-interaction models, 67
regulation, 107–8, 351
rodent models, 172–3
single-gene approaches, 107
studies, 104
early, 84
timing, 105
zebrafish, 55–6
- sleep–wake differences, transcriptional, 94

Index

- sleep-wake disorders
 epigenetic mechanisms, 134
 epigenetics, 133–5
 etiology, 133–4
 genetic epidemiology, 38
see also circadian rhythm sleep disorders (CRSDs)
- sleep-wake regulation
 and energy status, 94
 flip-flop model, 231
 genes, 22–4
 mechanisms, 76
- sleep-wake timing
 abnormal, 327
 biological bases, 313
 and diurnal preferences, 199–201
 preferences, variations, 197
- sleep-wake transition disorders
see sleep-wake disorders
- sleepiness
 daytime, 35
 and sleep disorders, 35–9
 and tumor necrosis factor- α , 306
see also excessive daytime sleepiness (EDS)
- sleeping sickness, African, 73–5
- sleepless* (*sss*) gene, 49
 identification, 107–8
- sleepwalking, twin studies, 38
- sleepwalking, twin studies, 37
- slow-wave activity (SWA), 94–6
 analysis, 148
 mechanisms, 148
 mice, 148–9
 regulation, 149
 research, 154–5
 and sleep duration, 190
- slow-wave sleep (SWS), 66, 208–9
 and declarative memory, 209–10, 214
 and emotional memory, 211
 and memory consolidation, 177–8
 and memory storage, 211–12
 and procedural memory, 210
 reduction, 327–8
see also non-rapid eye movement sleep (NREMS)
- Smith-Magenis syndrome (SMS)
 circadian clock genes and, 360
 etiology, 133–4
- Snap-25* gene, 357
- SNPs *see* single nucleotide polymorphisms
- social phobias, prevalence, 355–6
- soluble *N*-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) formation, 86
see also dominant-negative soluble *N*-ethylmaleimide-sensitive fusion protein attachment protein receptor (dnSNARE)
- somatostatin, and sleep deprivation, 92–3
- somnogenic substances
 glia, 86
 secretion
 astrocytes, 85–7
 microglia, 87–8
 oligodendrocytes, 87–8
- song learning, 178–9
- spaced training protocols, 45–6
- spatial maze tests, in sleep deprivation studies, 174
- SPATS2L* gene, 338
- specific phobias, prevalence, 355–6
- STAR protein, 48
- Starling resistors, upper airways modeling, 303–4
- starvation
 and ghrelin levels, 93–4
 and leptin levels, 93–4
 and *Lsd2* mutants, 98
 and waking, 96
- Streptococcus* spp. (bacteria), 238
- succinoxidase, 84
- sundowning, symptoms, 357
- superoxide dismutase 2 (SOD2), 131
- suprachiasmatic nucleus (SCN), 122, 147–8, 211–12
 and aging, 214–15
 and circadian clocks, 105, 150–1, 198–9
 epigenetic mechanisms, 127
 rodent studies, 151
 roles, 163
 synchronization, 122
- Suvorexant (MK-4305), 249
- switching, in brainstem, 104–5
- symptomatic narcolepsy, 260–8
 comorbidities, 268
 genetic disorders producing, 260–8
 future research, 268
 overview, 263–6
see also secondary narcolepsy
- synaptic consolidation, determinants, 220
- synaptic efficacy, markers, 222
- synaptic elements, regulators, and clock genes, 154
- synaptic functions, and sleep homeostasis, 149–50
- synaptic homeostasis, and sleep, 219–23
- synaptic homeostasis hypothesis (SHY), 220
- synaptic homeostasis theory, of sleep, 177–8
- synaptic plasticity, and sleep functions, 219–20
- synaptic strength
 and sleep deprivation, 177–8
 theory of, 143
- synaptic transmission, 46–8
- synaptobrevin II, 86
- synaptotagmin, 50–1
- Synechococcus* spp. (cyanobacteria), circadian rhythms, 123
- systems biology approaches
 to genetics of multiple sleep-wake traits, 104–16
 future trends, 116
- systems genetics
 advantages, 111–12
 applications, 112–14
 approaches, 104
 to genetic sleep research, 111–12
 candidate gene studies, 114
Drosophila spp. studies, 115–16
 future research, 116
 and microarray studies compared, 111–12
 murine studies, 114–15
- T-cell receptor (TCR), and narcolepsy, 255–7
- Tai2* flies, 45–6
- TALE homeobox genes, 341–2
- targeting induced local lesions in genomes (TILLING), applications, 60
- tau* mutant hamsters, 121
- TCRA* gene, 37, 255
 and narcolepsy, 255–7
- TEF* gene, and Parkinson's disease, 358
- ten-eleven translocation (TET) family, 128–9
- tetracycline transactivator (tTA), expression, 86
- TIM* gene, 353
 and schizophrenia, 357
- tim⁰¹* gene, 43–4
- time in bed (TIB), 100–1, 191
- time-of-day preferences, 164–5
- TIMELESS* gene, 26
 mutations, 43–4
- toll-like receptor 4 (TLR4), 87–8
- total sleep deprivation (TSD), 175
- TOX3* gene, 24, 341
 and restless legs syndrome, 343
- TRA@* gene, 25
- TRAJ* genes, 256
- transcription activator-like effector nucleases (TALENs), applications, 60
- transcription/translation oscillators, 120

- transgenic mice
BAC, 321
CSNK1D, 324
orexin/ataxin-3, 244–6, 250, 378–9
PER2, 321–4
- transmission disequilibrium test (TDT), 337–8
- TRAV* genes, 256
- TRIB1* gene, 100–1
- tribbles homolog 1 (*TRIB1*), roles, 100–1
- tribbles homolog 2 (*TRIB2*), 237
identification, 237–8
roles, 243–4
- Trypanosoma brucei* (protozoan), 73–5
- tuberomammillary nucleus (TMN), 66
- tumor necrosis factor- α (TNF- α)
and obstructive sleep apnea, 287–90
secretion, 85
and sleepiness, 306
- twin studies
chronic insomnia, 227, 229
circadian entrainment, 164–5
diurnal type, 34
electroencephalograms, 139–40
heritability, 6, 105–6
insomnias, 25–6, 36
morningness–eveningness, 23, 34
nightmares, 38
parasomnias, 38–9
recurrent hypersomnia, 274
restless legs syndrome, 39, 336
short sleepers, 192
sleep bruxism, 38
deprivation, 194
- disorders, 33
- enuresis, 38
- genetics, 140
- length, 34–5
- patterns, heritability, 22
- phenotypes, 1
- problems, 35–6
- quality, 35
- terrors, 37–8
- sleepwalking, 38
- sleepwalking, 37
see also dizygotic (DZ) twins;
monozygotic (MZ) twins
- tyrosine hydroxylase, 56
- upper airway inflammation, and
pediatric obstructive sleep
apnea, 302–3
- upper airways, modeling, 303–4
- upstream activation sequence (UAS),
46, 48
- uric acid, and pediatric obstructive
sleep apnea, 306
- use-dependency hypothesis, 94
- variable-number tandem repeats
(VNTRs), 165
in linkage mapping, 2–3
polymorphisms, 23, 329–31
primate-specific, 202
- vasodilatory substances, 73
- vasopressin, 56
- ventral lateral neurons (LNvs), 48, 50–1
- ventrolateral preoptic nucleus
(VLPO)
neurons, 75–6, 107
- signaling, 104–5
- viral vectors, 375
- wakefulness, 66
activation, 66–7
caffeine and, 78
maintenance, 44
microarray studies, 143
and orexin, 67, 249
prolonged, 143
- waking
promotion, 104–5
spontaneous, 50–1
and starvation, 96
- wheel-running behavior, mice, 321
- working memory, definition, 208
- X chromosome inactivation (XCI),
127–8
- Xenopus laevis* (African clawed frog),
meis1 gene, 341–2
- zebrafish
genetic screens, 60
locomotor activity, 56–7
melatonin, 214–15
reverse genetic approaches, 60
in sleep research, 54–62
sleep–wake cycles, 55–6
see also Danio rerio (zebrafish)
- zeitgebers, 164–5
early, 162
universal, 162–3
- zeitnehmer* loops, 163
- zinc finger nuclease (ZFN), 60